Sagitta Biotech
Developer of a non-replicating active virosome platform for vaccines, targeted oncology immunotherapies, and gene therapies. The platform is designed to express foreign proteins on vector surfaces and deliver self-replicating RNA payloads (up to 17 kb) into target cells. The company emphasizes modular vector engineering for rapid design, compatibility with existing vaccine manufacturing processes, and collaboration/co-development with biotech and pharma partners.
Industries
Nr. of Employees
small (1-50)
Products
Tetravalent influenza vaccine (under development)
A multivalent vaccine candidate intended to target multiple influenza strains using the active virosome platform; stated as a proof-of-concept program under development.
Active Virosome Technology Platform
A proprietary vaccine technology platform utilizing active virosomes that express surface antigens and carry antigen RNA for self-amplification, inducing both humoral and cellular immune responses.
Active virosomes for targeted gene therapies
Non-replicative active virosomes designed for safe, easy, and cost-effective targeted gene therapies, capable of delivering nucleic acid and carrying up to 6 foreign genes (17 kb).
Tetravalent Influenza Vaccine
A proof-of-concept tetravalent influenza vaccine candidate currently under development using Sagitta's active virosome technology.
Tetravalent influenza vaccine (under development)
A multivalent vaccine candidate intended to target multiple influenza strains using the active virosome platform; stated as a proof-of-concept program under development.
Active Virosome Technology Platform
A proprietary vaccine technology platform utilizing active virosomes that express surface antigens and carry antigen RNA for self-amplification, inducing both humoral and cellular immune responses.
Active virosomes for targeted gene therapies
Non-replicative active virosomes designed for safe, easy, and cost-effective targeted gene therapies, capable of delivering nucleic acid and carrying up to 6 foreign genes (17 kb).
Tetravalent Influenza Vaccine
A proof-of-concept tetravalent influenza vaccine candidate currently under development using Sagitta's active virosome technology.
Services
Collaborative development and technology access for custom vaccines, oncology, and gene therapy programs using the active virosome platform.
Collaborative development and technology access for custom vaccines, oncology, and gene therapy programs using the active virosome platform.
Expertise Areas
- Viral vector engineering
- Vaccine development (multivalent)
- Oncology-targeted immunotherapy
- Gene therapy vector development
Key Technologies
- Non-replicating virosome (viral-derived) vectors
- Self-amplifying (self-replicating) RNA
- Surface antigen display / receptor engineering
- Modular cassette cloning system
News & Updates
Participation listed for the World Vaccine Congress Europe (largest European meeting on vaccine R&D).
Participation listed for BIO2023, the BIO International Convention held in Boston, MA.
Participation listed for the Meet2Win Oncology Congress in Bordeaux, France.
Participation listed for BioWin Day, a regional life-science stakeholder event in Namur, Belgium.
Participation listed for the World Vaccine Congress Europe (largest European meeting on vaccine R&D).
Participation listed for BIO2023, the BIO International Convention held in Boston, MA.
Participation listed for the Meet2Win Oncology Congress in Bordeaux, France.
Participation listed for BioWin Day, a regional life-science stakeholder event in Namur, Belgium.